EU member states do not support "information to patients" strand of pharma package
This article was originally published in Scrip
22 member states of the EU are not in favour of the "information to patients" strand of the European Commission's proposed package of new pharma legislation, and it is likely that it will not go ahead, industry officials revealed at the annual meeting of the European pharmaceutical industry association, EFPIA, in Seville, Spain, this week.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.